Meningococcal infection in modern realities
- Authors: Koroleva I.S.1, Kоroleva M.A.1, Churilova N.S.1, Gritsay M.I.1, Beloshitsky G.V.1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Issue: Vol 13, No 2 (2023)
- Pages: 34-39
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/553237
- DOI: https://doi.org/10.18565/epidem.2023.13.2.34–9
- ID: 553237
Cite item
Abstract
There is a narrative review of the state of the problem of meningococcal infection (MI) in the modern aspect. The significant list of the specifc features of the diseases and the unprecedented risk of the infection contributed to the development of a rational panel of vaccines for specific immunoprophylaxis. The cost of the disease, by taking into account the total cost of its hospital treatment and the expenditures of when disease-disabling consequences occur, is depicted, by using the real scenarios as an example. The review demonstrates considerable changes in the epidemiological manifestations of MI in the Russian Federation and presents a reasonable warning that there may be the next periodic rise in the incidence of MI.
Full Text
About the authors
Irina S. Koroleva
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Author for correspondence.
Email: irina-korol@yandex.ru
ORCID iD: 0000-0003-0578-146X
MD; Head, Laboratory for the Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides
Russian Federation, MoscowMaria A. Kоroleva
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: korolevamaria389@gmail.com
ORCID iD: 0000-0002-2714-1191
MD; Senior Researcher, Laboratory for the Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides
Russian Federation, MoscowNadejda S. Churilova
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: n27101996@yandex.ru
ORCID iD: 0000-0001-5344-5829
Junior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides
Russian Federation, MoscowMaria I. Gritsay
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: maria-griz@mail.ru
ORCID iD: 0000-0002-6288-9074
Cand. Med. Sci., Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides
Russian Federation, MoscowGrigoriy V. Beloshitsky
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: g-belosh1@yandex.ru
ORCID iD: 0000-0002-4769-3890
Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides
Russian Federation, MoscowReferences
- Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 1969; 129: 1367–84. doi: 10.1084/jem.129.6.1367
- Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins С. Prevention of meningococcal disease by group C polysaccharide vaccines. N. Engl. J. Med. 1970; 282: 417–20. doi: 10.1056/NEJM197002192820803
- Dull P.M., McIntosh E.D. Meningococcal vaccine development – from glycoconjugates against MenACWY to proteins against MenB – potential for broad protection against meningococcal disease. Vaccine 2012; 30: B18–25. doi: 10.1016/j.vaccine.2012.01.062
- Vella M., Pace D. Glycoconjugate vaccines: an update. Expert Opin. Biol. Ther. 2015; 15: 529–46. doi: 10.1517/14712598.2015.993375
- Chen W.H., Neuzil K.M., Boyce C.R. ,Pasetti M.F., Reymann M.K., Martellet L. et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect. Dis. 2018; 18: 1088–96. doi: 10.1016/S1473-3099(18)30400-6
- Christodoulides M., Heckels J. Novel approaches to Neisseria meningitidis vaccine design. Pathog. Dis. 2018; 75: ftx033. doi: 10.1093/femspd/ftx033
- Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33: 530–41. doi: 10.1016/j.immuni.2010.09.017
- Rappuoli R., Pizza M., Masignani V., Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev. Vaccines 2018; 17: 1111–21. doi: 10.1080/14760584.2018.1547637
- Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S. et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 2009; 200: 379–89. doi: 10.1086/600141
- Perez J., Absalon J., Beeslaar J., Balmer P., Jansen K.U., Jones N.R et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev. Vaccines. 2018; 17: 461–77. doi: 10.1080/14760584.2018.1483726
- Hoiseth S.K., Murphy E., Andrew L., Vogel U., Frosch M., Hellenbrand W. et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr. Infect. Dis. J. 2013; 32: 1096–101. doi: 10.1097/INF.0b013e31829aa63b
- Rodrigues C.M.C., Lucidarme J., Borrow R., Smith A., Cameron J.C., Moxon E.R. et al. Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010–2016. Emerg. Infect. Dis. 2018; 24: 673–82. doi: 10.3201/eid2404.171480
- Jafri R.Z., Ali A., Messonnier N.E., Tevi-Benissan C., Durrheim D., Eskola J. et al. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 2013; (11): 17.
- Wang B., Santoreneos R., Giles L., Haji Ali Afzali H., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine 2019; 37: 2768–82. doi: 10.1016/j.vaccine.2019.04.020
- Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; (10): 853–61. doi: 10.1016/S1473-3099(10)70251-6
- Bénarda S., Wright C., Voisine J., Olivier C.W., Gaudelus J. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Journal of Infection and Public Health 2016; (9): 339–47. doi: 10.1016/j.jiph.2015.10.016
- Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs 2013; 15: 49–58. doi: 10.1007/s40272-012-0006-0
- Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. doi: 10.1016/j.vaccine.2014.07.019
- О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2020. 340 с. [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report]. Moscow, 2020. 340 p. (In Russ.).
- Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиология и инфекционные болезни 2014; (2): 73–9. Kostyukova N.N., Bekhalo V.A., Chernyshova T.F. [Meningococcal infection in the Russian Federation: past and immediate prospects]. Epidemiology and infectious diseases 2014; (2): 73–9. (In Russ.).
- Meningococcal vaccines: WHO position paper, November 2011. Weekly epidemiological record 2011; 47(86); 521–40. https://www.who. int/publications/i/item/WER8647